Talwar G P, Sharma N C, Dubey S K, Salahuddin M, Das C, Ramakrishnan S, Kumar S, Hingorani V
Proc Natl Acad Sci U S A. 1976 Jan;73(1):218-22. doi: 10.1073/pnas.73.1.218.
The immunogenicity of the conjugate prepared from "processed" beta-subunit of human chorionic gonadotropin (choriogonadotropin, HCG) and tetanus toxoid has been studied in animals and a human subject. The conjugate elicited the formation of high-affinity (Ka = 10(9)-10(11) M-1) anti-HCG and anti-tetanus antibodies. On primary immunization, the antibody, response lasted for several months. Repeat injection of the conjugate in the declining phase of antibody titers produced a booster response without a lag period. The antibodies reacted with the beta-subunit of HCG and the complete HCG molecule but were devois of significant crossreactivity with human growth hormone, placental lactogen, follicle-stimulating hormone, thyroid-stimulating hormone, and luteinizing hormone at tonic and surge levels. The antibodies were competent for neutralizing the biological activity of HCG in the mouse uterine weight gain assay, the ventral prostate weight gain assay, and the radioligand assay for binding of 125I-labeled HCG to receptors on corpus luteum. HCG (5000 international units) administered to an immunized subject was completely bound by circulating antibodies. Administration of HCG (in contrast to conjugate) was without booster effect on anti-HCG titers.
已在动物和一名人类受试者中研究了由人绒毛膜促性腺激素(绒毛膜促性腺激素,HCG)“加工”的β亚基与破伤风类毒素制备的偶联物的免疫原性。该偶联物引发了高亲和力(Ka = 10⁹ - 10¹¹ M⁻¹)抗HCG和抗破伤风抗体的形成。初次免疫时,抗体反应持续数月。在抗体滴度下降阶段重复注射偶联物产生了无滞后期的增强反应。这些抗体与HCG的β亚基和完整的HCG分子发生反应,但在基础水平和峰值水平时与人生长激素、胎盘催乳素、促卵泡激素、促甲状腺激素和促黄体生成素无明显交叉反应。在小鼠子宫增重试验、腹侧前列腺增重试验以及125I标记的HCG与黄体受体结合的放射性配体试验中,这些抗体能够中和HCG的生物活性。给予一名免疫受试者5000国际单位的HCG完全被循环抗体结合。给予HCG(与偶联物相反)对抗HCG滴度无增强作用。